drugset / Trial / NCT03819270

A Safety Study of LY3372689 Given By Mouth to Healthy Participants

NCT03819270 ↗

Phase 1 Completed 23 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive up to 3 doses of LY3372689 or placebo. The study will last about 12 weeks, including screening.

Timeline

Start
2019-02-05
Primary completion
2019-06-23
Completion
2019-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject ceperognastat Small molecule — Oral

Indications

No indication recorded.